13,260 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Purchased by Hunter Associates Investment Management LLC

Hunter Associates Investment Management LLC purchased a new stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor purchased 13,260 shares of the company’s stock, valued at approximately $92,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ZVRA. Mystic Asset Management Inc. grew its stake in shares of Zevra Therapeutics by 15.4% during the first quarter. Mystic Asset Management Inc. now owns 266,297 shares of the company’s stock valued at $1,545,000 after buying an additional 35,514 shares during the last quarter. Retirement Planning Co of New England Inc. boosted its holdings in Zevra Therapeutics by 11.0% during the 1st quarter. Retirement Planning Co of New England Inc. now owns 430,193 shares of the company’s stock valued at $2,495,000 after acquiring an additional 42,766 shares during the period. Vanguard Group Inc. grew its position in Zevra Therapeutics by 3.6% in the 1st quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock valued at $9,883,000 after acquiring an additional 58,866 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in Zevra Therapeutics in the first quarter worth $64,000. Finally, Jacobs Levy Equity Management Inc. lifted its position in shares of Zevra Therapeutics by 102.4% during the first quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock worth $201,000 after purchasing an additional 17,557 shares during the last quarter. 35.03% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ZVRA has been the topic of a number of research analyst reports. Canaccord Genuity Group cut their price target on shares of Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Wednesday, September 18th. Roth Mkm lifted their target price on Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Guggenheim assumed coverage on Zevra Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $20.00 price target on the stock. JMP Securities began coverage on Zevra Therapeutics in a research note on Tuesday, September 24th. They set an “outperform” rating and a $17.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zevra Therapeutics in a research note on Friday, October 11th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $20.83.

Zevra Therapeutics Price Performance

Shares of ZVRA stock opened at $8.26 on Wednesday. The company has a market cap of $434.62 million, a P/E ratio of -4.92 and a beta of 1.94. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.00 and a quick ratio of 2.00. The stock’s 50-day moving average is $7.67 and its 200 day moving average is $6.12. Zevra Therapeutics, Inc. has a 1-year low of $3.89 and a 1-year high of $8.95.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. The firm had revenue of $4.45 million during the quarter, compared to analysts’ expectations of $4.08 million. During the same period in the previous year, the firm earned ($0.15) EPS. Research analysts predict that Zevra Therapeutics, Inc. will post -1.63 earnings per share for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.